Literature DB >> 95670

Immunological induction of T lymphocytes: role of antigen and the lymphocyte costimulator.

K J Lafferty1, H S Warren, J A Woolnough, D W Talmage.   

Abstract

In vitro T cell activation requires both antigen presentation and a second stimulus provided by the lymphocyte costimulator. Neither alone is sufficient to induce specific T cell activation. The S+ phenotype of stimulating cells is dependent on the metabolic activity of these cells. This finding is consistent with the notion that production and/or release of the costimulator is a function of metabolically active cells. The costimulator acts at an early stage of the interaction between lymphocyte and antigen, and the costimulator, or a separate maintenance factor, is required throughout the culture period for the expression of full cytotoxic activity. The lymphocyte costimulator is not strain specific but is phylogenetically specific. The activation of cytotoxic T cells by S+ cells is also phylogenetically specific, and this specificity of cellular activation can be accounted for by the species specificity of the lymphocyte costimulator.

Mesh:

Substances:

Year:  1978        PMID: 95670

Source DB:  PubMed          Journal:  Blood Cells        ISSN: 0340-4684


  12 in total

1.  Natural Tregs, CD4+CD25+ inhibitory hybridomas, and their cell contact dependent suppression.

Authors:  Elizabeth H Field; Katarina Kulhankova; Mohamed E Nasr
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

2.  Ultraviolet light-induced suppression of antigen presentation.

Authors:  C W Spellman; T B Tomasi
Journal:  J Clin Immunol       Date:  1983-04       Impact factor: 8.317

3.  Identification of a T cell-derived b cell growth factor distinct from interleukin 2.

Authors:  M Howard; J Farrar; M Hilfiker; B Johnson; K Takatsu; T Hamaoka; W E Paul
Journal:  J Exp Med       Date:  1982-03-01       Impact factor: 14.307

4.  Theory and practice of immunoregulation by tissue treatment prior to transplantation.

Authors:  K J Lafferty; S J Prowse
Journal:  World J Surg       Date:  1984-04       Impact factor: 3.352

Review 5.  Checkpoint inhibitors in lung cancer: latest developments and clinical potential.

Authors:  Gustavo Schvartsman; Renata Ferrarotto; Erminia Massarelli
Journal:  Ther Adv Med Oncol       Date:  2016-07-26       Impact factor: 8.168

6.  Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

Authors:  M A Cheever; P D Greenberg; A Fefer; S Gillis
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

7.  Elimination of T cell reactivity to pancreatic β cells and partial preservation of β cell activity by peptide blockade of LFA-1:ICAM-1 interaction in the NOD mouse model.

Authors:  Abby L Dotson; Lesya Novikova; Lisa Stehno-Bittel; Stephen H Benedict
Journal:  Clin Immunol       Date:  2013-05-09       Impact factor: 3.969

8.  Long-term culture of normal mouse B lymphocytes.

Authors:  M Howard; S Kessler; T Chused; W E Paul
Journal:  Proc Natl Acad Sci U S A       Date:  1981-09       Impact factor: 11.205

9.  Role of interleukin 1 in anti-immunoglobulin-induced B cell proliferation.

Authors:  M Howard; S B Mizel; L Lachman; J Ansel; B Johnson; W E Paul
Journal:  J Exp Med       Date:  1983-05-01       Impact factor: 14.307

Review 10.  Immunotherapies for malignant glioma.

Authors:  Vassiliki A Boussiotis; Alain Charest
Journal:  Oncogene       Date:  2017-12-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.